Key result
Pediatric heart failure drug development demands mechanism-based classification and adaptive trial designs.
Answers are grounded in this paper and cite their sources.
This review highlights the unmet need in pediatric heart failure drug development and proposes innovations including a mechanism-of-action driven phenotype classification system, pharmacokinetic extrapolation, bridging biomarkers, and adaptive trial designs.
Pediatric heart failure (HF) remains an important area of unmet medical need. Pharmacological treatments primarily consist of adult drugs used off label in children. HF regulatory guidance specific to pediatric drug development is limited. The diversity in underlying pathophysiology necessitates a shift toward a mechanism-of-action driven approach. We examine the current landscape of pediatric HF, identify key challenges and opportunities for drug development, and discuss a paradigm shift to a new high-level HF phenotype classification system for pediatric HF. Pediatric extrapolation utilizing pharmacokinetics and bridging biomarkers, especially given the absence of validated surrogate endpoints, remains a promising strategy for subsets of pediatric HF physiology. Ongoing reorganization of pediatric regulatory frameworks presents a key opportunity to promote harmonization between pediatric requirements from regulatory agencies across jurisdictions. We describe innovation in pediatric HF treatment through use of extrapolation, bridging biomarkers, and adaptive trial design.
No takes yet. Share an insight, caveat, or question.
Sekar et al. (2026) conducted a review in Pediatric heart failure. Pediatric heart failure drug development requires a paradigm shift toward mechanism-of-action phenotype classification, pharmacokinetic extrapolation, bridging biomarkers, and adaptive trial design.
Synapse has enriched 10 related papers. Consider them for comparative context: